Improved rapid diagnostic tests to detect syphilis and yaws: a systematic review and meta-analysis. (30th September 2022)

• Record Type: Journal Article
• Authors: Zhang, Ying; Goh, Su Mei; Mello, Maeve B; Baggaley, Rachel C; Wi, Teodora; Johnson, Cheryl C; Asiedu, Kingsley B; Marks, Michael; Pham, Minh D; Fairley, Christopher K; Chow, Eric P F; Mitjà, Oriol; Toskin, Igor; Ballard, Ronald C; Ong, Jason J
• Is Part Of: Sexually transmitted infections. Volume 98:issue 8(2022)
• Page Start: 608
• Page End: 616
• Publication Date: 2022-09-30
• Subjects: SYPHILIS -- YAWS -- DIAGNOSIS; Sexually transmitted diseases -- Periodicals; HIV infections -- Periodicals; 616.951005
• DOI: 10.1136/sextrans-2022-055546
• Languages: English
• ISSNs: 1368-4973

Abstract

Abstract : Background: Current rapid tests for syphilis and yaws can detect treponemal and non-treponemal antibodies. We aimed to critically appraise the literature for rapid diagnostic tests (RDTs) which can better distinguish an active infection of syphilis or yaws. Methods: We conducted a systematic review and meta-analysis, searching five databases between January 2010 and October 2021 (with an update in July 2022). A generalised linear mixed model was used to conduct a bivariate meta-analysis for the pooled sensitivity and specificity. Heterogeneity was assessed using the I 2 statistic. We used the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) to assess the risk of bias and Grading of Recommendations, Assessment, Development and Evaluations (GRADE) to evaluate the certainty of evidence. Results: We included 17 studies for meta-analyses. For syphilis, the pooled sensitivity and specificity of the treponemal component were 0.93 (95% CI: 0.86 to 0.97) and 0.98 (95% CI: 0.96 to 0.99), respectively. For the non-treponemal component, the pooled sensitivity and specificity were 0.90 (95% CI: 0.82 to 0.95) and 0.97 (95% CI: 0.92 to 0.99), respectively. For yaws, the pooled sensitivity and specificity of the treponemal component were 0.86 (95% CI: 0.66 to 0.95) and 0.97 (95% CI: 0.94 to 0.99), respectively. For the non-treponemal component, the pooled sensitivity and specificity were 0.80 (95% CI: 0.55 to 0.93) and 0.96 (95% CI: 0.92 to 0.98), respectively. Conclusions: RDTs that can differentiate between active and previously treated infections could optimise management by providing same-day treatment and reducing unnecessary treatment. PROSPERO registration number: CRD42021279587.